The University of Chicago Header Logo

Connection

Christopher M. Gomez to Middle Aged

Back to Details
This is a "connection" page, showing publications Christopher M. Gomez has written about Middle Aged.
Christopher M. Gomez
Connection Strength
0.421
Middle Aged
  1. Evaluation of parkinsonism and striatal dopamine transporter loss in patients with spinocerebellar ataxia type 6. J Neurol. 2016 Nov; 263(11):2302-2307.
    View in: PubMed
    Score: 0.035
  2. Loss of intrinsic organization of cerebellar networks in spinocerebellar ataxia type 1: correlates with disease severity and duration. Cerebellum. 2011 Jun; 10(2):218-32.
    View in: PubMed
    Score: 0.025
  3. Longitudinal cerebral blood flow changes during speech in hereditary ataxia. Brain Lang. 2010 Jul; 114(1):43-51.
    View in: PubMed
    Score: 0.023
  4. Evaluation of sleep and daytime somnolence in spinocerebellar ataxia type 6 (SCA6). Neurology. 2006 May 09; 66(9):1430-1.
    View in: PubMed
    Score: 0.017
  5. Spinocerebellar ataxia type 26 maps to chromosome 19p13.3 adjacent to SCA6. Ann Neurol. 2005 Mar; 57(3):349-54.
    View in: PubMed
    Score: 0.016
  6. Antigliadin antibodies in Huntington's disease. Neurology. 2004 Jan 13; 62(1):132-3.
    View in: PubMed
    Score: 0.015
  7. Novel CACNA1A mutation causes febrile episodic ataxia with interictal cerebellar deficits. Ann Neurol. 2003 Dec; 54(6):725-31.
    View in: PubMed
    Score: 0.015
  8. Scoliosis in Friedreich's ataxia: longitudinal characterization in a large heterogeneous cohort. Ann Clin Transl Neurol. 2021 06; 8(6):1239-1250.
    View in: PubMed
    Score: 0.012
  9. The impact of ethnicity on the clinical presentations of spinocerebellar ataxia type 3. Parkinsonism Relat Disord. 2020 03; 72:37-43.
    View in: PubMed
    Score: 0.011
  10. Tremor in the Degenerative Cerebellum: Towards the Understanding of Brain Circuitry for Tremor. Cerebellum. 2019 Jun; 18(3):519-526.
    View in: PubMed
    Score: 0.011
  11. Targeted exome analysis identifies the genetic basis of disease in over 50% of patients with a wide range of ataxia-related phenotypes. Genet Med. 2019 01; 21(1):195-206.
    View in: PubMed
    Score: 0.010
  12. Neurochemical abnormalities in premanifest and early spinocerebellar ataxias. Ann Neurol. 2018 04; 83(4):816-829.
    View in: PubMed
    Score: 0.010
  13. Spinocerebellar ataxia type 6: gaze-evoked and vertical nystagmus, Purkinje cell degeneration, and variable age of onset. Ann Neurol. 1997 Dec; 42(6):933-50.
    View in: PubMed
    Score: 0.010
  14. C9orf72 repeat expansions as genetic modifiers for depression in spinocerebellar ataxias. Mov Disord. 2018 03; 33(3):497-498.
    View in: PubMed
    Score: 0.010
  15. Dystonia and ataxia progression in spinocerebellar ataxias. Parkinsonism Relat Disord. 2017 Dec; 45:75-80.
    View in: PubMed
    Score: 0.010
  16. Postural Tremor and Ataxia Progression in Spinocerebellar Ataxias. Tremor Other Hyperkinet Mov (N Y). 2017; 7:492.
    View in: PubMed
    Score: 0.010
  17. The Initial Symptom and Motor Progression in Spinocerebellar Ataxias. Cerebellum. 2017 06; 16(3):615-622.
    View in: PubMed
    Score: 0.009
  18. Trial-to-trial Adaptation: Parsing out the Roles of Cerebellum and BG in Predictive Motor Timing. J Cogn Neurosci. 2016 Jul; 28(7):920-34.
    View in: PubMed
    Score: 0.009
  19. Depression and clinical progression in spinocerebellar ataxias. Parkinsonism Relat Disord. 2016 Jan; 22:87-92.
    View in: PubMed
    Score: 0.008
  20. Early Cerebellar Network Shifting in Spinocerebellar Ataxia Type 6. Cereb Cortex. 2016 07; 26(7):3205-18.
    View in: PubMed
    Score: 0.008
  21. Cerebrospinal Fluid Biomarkers in Spinocerebellar Ataxia: A Pilot Study. Dis Markers. 2015; 2015:413098.
    View in: PubMed
    Score: 0.008
  22. Clinical evaluation of eye movements in spinocerebellar ataxias: a prospective multicenter study. J Neuroophthalmol. 2015 Mar; 35(1):16-21.
    View in: PubMed
    Score: 0.008
  23. Coenzyme Q10 and spinocerebellar ataxias. Mov Disord. 2015 Feb; 30(2):214-20.
    View in: PubMed
    Score: 0.008
  24. Analysis of the visual system in Friedreich ataxia. J Neurol. 2013 Sep; 260(9):2362-9.
    View in: PubMed
    Score: 0.007
  25. FXN methylation predicts expression and clinical outcome in Friedreich ataxia. Ann Neurol. 2012 Apr; 71(4):487-97.
    View in: PubMed
    Score: 0.007
  26. Role of botulinum toxin-A in refractory idiopathic overactive bladder patients without detrusor overactivity. Int Urol Nephrol. 2012 Feb; 44(1):91-7.
    View in: PubMed
    Score: 0.006
  27. Distinct neurochemical profiles of spinocerebellar ataxias 1, 2, 6, and cerebellar multiple system atrophy. Cerebellum. 2011 Jun; 10(2):208-17.
    View in: PubMed
    Score: 0.006
  28. The neural substrate of predictive motor timing in spinocerebellar ataxia. Cerebellum. 2011 Jun; 10(2):233-44.
    View in: PubMed
    Score: 0.006
  29. Speech characteristics associated with three genotypes of ataxia. J Commun Disord. 2011 Jul-Aug; 44(4):478-92.
    View in: PubMed
    Score: 0.006
  30. Frequency of KCNC3 DNA variants as causes of spinocerebellar ataxia 13 (SCA13). PLoS One. 2011 Mar 29; 6(3):e17811.
    View in: PubMed
    Score: 0.006
  31. (1)H MR spectroscopy in Friedreich's ataxia and ataxia with oculomotor apraxia type 2. Brain Res. 2010 Oct 28; 1358:200-10.
    View in: PubMed
    Score: 0.006
  32. Neurochemical alterations in spinocerebellar ataxia type 1 and their correlations with clinical status. Mov Disord. 2010 Jul 15; 25(9):1253-61.
    View in: PubMed
    Score: 0.006
  33. What is the predictive value of urodynamics to reproduce clinical findings of urinary frequency, urge urinary incontinence, and/or stress urinary incontinence? Int Urogynecol J. 2010 Oct; 21(10):1205-9.
    View in: PubMed
    Score: 0.006
  34. Measuring the rate of progression in Friedreich ataxia: implications for clinical trial design. Mov Disord. 2010 Mar 15; 25(4):426-32.
    View in: PubMed
    Score: 0.006
  35. Survival disparities among African American women with invasive bladder cancer in Florida. Cancer. 2009 Sep 15; 115(18):4196-209.
    View in: PubMed
    Score: 0.005
  36. Health related quality of life measures in Friedreich Ataxia. J Neurol Sci. 2008 Sep 15; 272(1-2):123-8.
    View in: PubMed
    Score: 0.005
  37. Antioxidant use in Friedreich ataxia. J Neurol Sci. 2008 Apr 15; 267(1-2):174-6.
    View in: PubMed
    Score: 0.005
  38. Impaired predictive motor timing in patients with cerebellar disorders. Exp Brain Res. 2007 Jun; 180(2):355-65.
    View in: PubMed
    Score: 0.005
  39. Measuring Friedreich ataxia: complementary features of examination and performance measures. Neurology. 2006 Jun 13; 66(11):1711-6.
    View in: PubMed
    Score: 0.004
  40. Depth perception in cerebellar and basal ganglia disease. Exp Brain Res. 2006 Oct; 175(1):165-76.
    View in: PubMed
    Score: 0.004
  41. Mapping cerebral blood flow during speech production in hereditary ataxia. Neuroimage. 2006 May 15; 31(1):246-54.
    View in: PubMed
    Score: 0.004
  42. Measuring Friedreich ataxia: Interrater reliability of a neurologic rating scale. Neurology. 2005 Apr 12; 64(7):1261-2.
    View in: PubMed
    Score: 0.004
  43. Deficits in ocular and manual tracking due to episodic ataxia type 2. Mov Disord. 2004 Jul; 19(7):778-787.
    View in: PubMed
    Score: 0.004
  44. Hereditary cerebellar ataxia progressively impairs force adaptation during goal-directed arm movements. J Neurophysiol. 2004 Jan; 91(1):230-8.
    View in: PubMed
    Score: 0.004
  45. Dysfunction of the basal ganglia, but not the cerebellum, impairs kinaesthesia. Brain. 2003 Oct; 126(Pt 10):2312-22.
    View in: PubMed
    Score: 0.004
  46. Incidence of dominant spinocerebellar and Friedreich triplet repeats among 361 ataxia families. Neurology. 1998 Dec; 51(6):1666-71.
    View in: PubMed
    Score: 0.003
  47. Analysis of the dynamic mutation in the SCA7 gene shows marked parental effects on CAG repeat transmission. Hum Mol Genet. 1998 Mar; 7(3):525-32.
    View in: PubMed
    Score: 0.002
  48. Frontal lobe function in progressive supranuclear palsy. Arch Neurol. 1990 May; 47(5):553-8.
    View in: PubMed
    Score: 0.001
  49. Physostigmine treatment of progressive supranuclear palsy. Ann Neurol. 1989 Sep; 26(3):404-7.
    View in: PubMed
    Score: 0.001
  50. Memory impairment in patients with progressive supranuclear palsy. Arch Neurol. 1989 Jul; 46(7):765-7.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.